Review Article
A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
Table 2
Efficacy outcomes of all tested patients with urothelial carcinoma in US FDA-approved PD-1/PD-L1 inhibitor trials.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORR: objective response rate; DoR: median duration of response; PFS: median progression-free survival; OS: median overall survival; HR: hazard ratio; CI: confidence interval; NR: not reached; NE: not estimable; follow-up at least 13 weeks; follow-up at least 6 months. |